Free Submission Public Relations & NewsPR-inside.com
Home
Deutsch English

Business

Free Research Reports on FINL, ONCY, PCS and RPRX Issued by the Bedford Report Note to Editors: The Following Is an Investment Opinion Being Issued by the EQUITY NEWS CIRCUIT


Print article Print article
© Marketwire 2013
2013-04-01 14:18:58 -

NEW YORK, NY -- (Marketwire) -- 04/01/13 -- The Bedford Report has released new equity reports today. As a leading provider of free in depth reports and timely market updates, Bedford is an essential resource for hundreds of thousands of investors across the country.



Finish Line Inc. (NASDAQ: FINL) shares spiked 7.11 percent on volume of over 2.05 million shares traded Thursday to close at $19.59 a share. The company reported consolidated net sales for the fiscal year 2013 totaled $1.44 billion, a year-over-year increase of 5.4 percent.



Find out more about Finish Line including full access to the free equity report at: www.BedfordReport.com/FINL : www.bedfordreport.com/FINL





Oncolytics Biotech, Inc. (NASDAQ: ONCY)(TSX: ONC) shares gained 3.34 percent on volume of nearly 1 million shares traded Thursday to close at $3.09 a share. The company reported positive results from a recent U.S. Phase 2 study of Reolysin for the treatment of squamous cell carcinoma of the lung.



Find out more about Oncolytics Biotech including full access to the free equity report at: www.BedfordReport.com/ONCY : www.bedfordreport.com/ONCY



MetroPCS Communications Inc. (NYSE: PCS) shares spiked 3.51 percent on nearly three times the average daily volume Thursday to close at $10.90 a share. The Wall Street Journal recently reported that proxy adviser Glass Lewis & Co. has recommended shareholders vote against the company's proposed merger with Deutsche Telekom AG's T-Mobile USA.



Find out more about MetroPCS Communications including full access to the free equity report at: www.BedfordReport.com/PCS : www.bedfordreport.com/PCS



Repros Therapeutics Inc. (NASDAQ: RPRX) shares soared 76.34 percent on more than ten times the average daily volume Thursday to close at $16.10 a share. The company reported both met both co-primary endpoints mandated by the FDA were met in the first pivotal study of Androxal.



Find out more about Repros Therapeutics including full access to the free equity report at: www.BedfordReport.com/RPRX : www.bedfordreport.com/RPRX



Disclaimer: Information, opinions and analysis contained herein are based on sources believed to be reliable, but no representation, expressed or implied, is made as to its accuracy, completeness or correctness. The opinions contained herein reflect our current judgment and are subject to change without notice. We accept no liability for any losses arising from an investor's reliance on or use of this report. This report is for information purposes only, and is neither a solicitation to buy nor an offer to sell securities. Certain information included herein is forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements concerning manufacturing, marketing, growth, and expansion. Such forward-looking information involves important risks and uncertainties that could affect actual results and cause them to differ materially from expectations expressed herein. A third party, Providence Media Strategies LLC has paid Equity News Circuit five hundred dollars for the publication of this news release. Neither Equity News Circuit, nor the hiring party, has a financial relationship with any company whose stock is mentioned in this release. Neither Equity News Circuit nor the hiring party are a registered investment advisor, and nothing in this report is intended as a solicitation to buy or sell any security.




Contact Information:

Equity News Circuit
Email Contact : www2.marketwire.com/mw/emailprcntct?id=EE0F612DEE736691



Press Information:




Contact Person:


Disclaimer: (c) 2014 Market Wire. All of the press releases contained herein are protected by copyright and other applicable laws, treaties and conventions. Information contained in the releases is furnished by Market Wire's, who warrant that they are solely responsible for the content, accuracy and originality of the information contained therein. All reproduction, other than for an individual user's personal reference, is prohibited without prior written permission.
Latest News
Read the Latest News
www.newsenvoy.com

 


Terms & Conditions | Privacy | About us | Contact PR-inside.com | BidVertiser